Kancera Overview

  • Status
  • Public
  • Employees
  • 9
Employees
  • Stock Symbol
  • KAN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.28
  • (As of Wednesday Closing)

Kancera General Information

Description

Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Karolinska Institutet Science Park
  • Banvaktsvägen 22
  • 171 48 Solna
  • Sweden
+46 08-501 000 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kancera Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.28 $0.28 $0.03 - $0.49 $131M 474M 14.3M -$0.02

Kancera Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 147,980 9,925 14,653 29,813
Revenue 10 340 41 13
EBITDA (4,181) (3,782) (5,217) (6,449)
Net Income (4,490) (3,816) (5,279) (6,575)
Total Assets 10,773 4,744 5,066 6,257
Total Debt 0 434 73 482
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kancera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and
Biotechnology
Solna, Sweden
9 As of 2020

00000000

smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000 000000000
Melbourne, Australia
00 As of 0000
00.00 0000-00-00
000000&0

000000 0

itation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000000000000
Amsterdam, Netherlands
00.000
00000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kancera Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Clinuvel Pharmaceuticals Corporation Melbourne, Australia 00 000000&0
000000 00000000000 Venture Capital-Backed Amsterdam, Netherlands 00.000 00000000000 00.000
To view Kancera’s complete competitors history, request access »

Kancera Executive Team (1)

Name Title Board Seat Contact Info
Thomas Olin Ph.D Founder, Chief Executive Officer & Board Member
To view Kancera’s complete executive team members history, request access »

Kancera Board Members (1)

Name Representing Role Since
000000 0000 00.0 Kancera Founder, Chief Executive Officer & Board Member 000 0000
To view Kancera’s complete board members history, request access »

Kancera Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kancera Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 17-Feb-2011 000000000000000000 000.00 Drug Discovery 000000 0000 00.0
To view Kancera’s complete acquisitions history, request access »